Analysts weigh Novo Nordisk's position as GLP-1 competition intensifies
Commentary examines the Danish drugmaker's five-year outlook as rivals crowd the obesity and diabetes drug market.
TR
By Tom Reyes · Markets Editor
Sep 16 12:20 ETSource: Currently.com
The wire
- 01An investment commentary assesses Novo Nordisk's prospects over the next five years amid growing GLP-1 competition.
- 02Novo's dominance in incretin drugs faces pressure from Eli Lilly and newer entrants.
- 03The piece is opinion; no new company guidance or data was reported.
From the source
Read at news.google.comWhere Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?